Digestive Diseases and Sciences

, Volume 55, Issue 8, pp 2309–2315 | Cite as

Diagnostic Role and Clinical Association of ASCA and ANCA in Brazilian Patients with Inflammatory Bowel Disease

  • Renato Mitsunori Nisihara
  • Wilson Beleski de Carvalho
  • Shirley Ramos da Rosa Utiyama
  • Heda Amarante
  • Márcia Luiza Baptista
Original Article



Anti-Saccharomyces cerevisae antibody (ASCA) and perinuclear anti-neutrophil cytoplasmatic antibody (pANCA) remain the most well-established markers in inflammatory bowel disease (IBD), and both may be associated with disease phenotype.


To determine the utility of ASCA and pANCA as markers in a Brazilian cohort of IBD patients.

Materials And Methods

A total of 90 patients with ulcerative colitis (UC), 77 patients with Crohn’s disease (CD), and 57 healthy individuals were included in the study. ASCA was determined by enzyme-linked immunosorbent assay (ELISA) and pANCA by immunofluorescence assay.


In support of diagnosis of UC, the sensitivity and specificity of pANCA were 51% and 100%, respectively. ASCA (IgA or IgG isotypes) presented sensitivity of 62% and specificity of 93% for CD. The combination of ASCA negativity and pANCA positivity (ASCA−/pANCA+) displayed sensitivity of 43% and specificity of 100% for diagnosis to UC. In CD patients, ASCA+/pANCA− presented sensitivity and specificity of 57% and 93%, respectively. Additionally, ASCA positivity correlated with early age at disease onset and ileal location in CD patients. In UC patients, pANCA positivity was correlated with pancolitis or left colitis.


The results evidenced that low sensitivity of ASCA and pANCA markers limits their use in IBD screening in the general population; however, their specificity may contribute to differentiation between CD and UC in IBD patients. Our study lends further support to the suggestion that serologic assessment identifies different subtypes of IBD.


Inflammatory bowel disease Ulcerative colitis Crohn’s disease ASCA ANCA Disease phenotype 



The authors thanks to Dr. Rhian Phillips for revision of the manuscript.


The authors inform that there are no potential conflicts of interest regarding specific financial interests (personal or institutional).


  1. 1.
    Bamias G, Cominelli F. Imunopathogenesis of inflammatory bowel disease: Current concepts. Curr Opin Gastroenterol. 2007;23:365–369.CrossRefPubMedGoogle Scholar
  2. 2.
    Duerr RH. Update on the genetics of inflammatory bowel disease. J Clin Gastroenterol. 2003;37:358–367.CrossRefPubMedGoogle Scholar
  3. 3.
    Gaburri PD, Castro LEV, Ferreira JOD. Epidemiology, clinical features and evolution of Crohn’s disease: A study of 60 cases. Arq Gastroenterol. 1998;35:240–246.PubMedGoogle Scholar
  4. 4.
    Souza MHLP, Troncon LEA, Rodrigues CM, et al. Trends in the occurrence (1980–1999) and clinical features of Crohn’s disease and ulcerative colitis in a university hospital in southeastern Brazil. Arq Gastroenterol. 2002;39:98–105.CrossRefPubMedGoogle Scholar
  5. 5.
    Papp M, Norman GL, Altorjay I, Lakatos PL. Utility of serological markers in inflammatory bowel diseases: Gadget or magic? World J Gastroenterol. 2007;13:2028–2036.PubMedGoogle Scholar
  6. 6.
    Beaven SW, Abreu MT. Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol. 2004;20:318–327.CrossRefPubMedGoogle Scholar
  7. 7.
    Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54:1232–1236.CrossRefPubMedGoogle Scholar
  8. 8.
    Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: Prevalence and diagnostic role. Gut. 1998;42:788–791.PubMedCrossRefGoogle Scholar
  9. 9.
    Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96:730–734.CrossRefPubMedGoogle Scholar
  10. 10.
    Sandborn WJ, Loftus EV Jr, Colombel JF, et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis. 2001;7:192–201.CrossRefPubMedGoogle Scholar
  11. 11.
    Koutrobakis IE, Petinaki E, Mouzas IA. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96:449–454.Google Scholar
  12. 12.
    Saibeni S, Folli C, de Franchis R, Borsi G, Vecchi M. Diagnostic role and clinical correlates of anti Sacharomyces cerevisiae antibodies and anti neutrophil cytoplasmic antibodies (ANCA) in Italian patients with inflammatory bowel disease. Dig Liver Dis. 2003;35:862–868.CrossRefPubMedGoogle Scholar
  13. 13.
    Klebl FH, Bataille F, Bertea CR, et al. Association of perinuclear antineutrophil cytopalsmic antibodies and anti-Sacchoromyces cerevisiae antibodies with Vienna classification subtypes of Crohn’s disease. Inflamm Bowel Dis. 2003;9:302–307.CrossRefPubMedGoogle Scholar
  14. 14.
    Mokrowiecka A, Gasiorowska A, Maleccka-Panas E. Panca and ASCA in the diagnosis of different subtypes of inflammatory bowel disease. Hepatogastroenterol. 2007;54:1443–1448.Google Scholar
  15. 15.
    Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;11:353–356.Google Scholar
  16. 16.
    Harvey RF, Bradshaw JM. A simple index of Crohn’s disease activity. Lancet. 1980;1:514.CrossRefPubMedGoogle Scholar
  17. 17.
    Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006;52:171–181.CrossRefPubMedGoogle Scholar
  18. 18.
    Reese GE, Constantinides VA, Simillis C, et al. Diagnostic precision of anti-Sacchacomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 2006;101:2410–2422.CrossRefPubMedGoogle Scholar
  19. 19.
    Cabral VL, Mizputen SJ, Catapani WR. Anti neutrophil cytoplasmatic antibodies in brazilian patients with inflammatory bowel disease. Hepatogastroenterol. 2003;50:412–415.Google Scholar
  20. 20.
    Steinwurz F, Scheinberg M. Serologic diagnosis of inflammatory bowel disease (ASCA and ANCA): Evaluation of 70 cases. GED. 2001;20:41–42.Google Scholar
  21. 21.
    Vermeire S, Joossens S, Peeters M, et al. Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology. 2001;120:827–833.CrossRefPubMedGoogle Scholar
  22. 22.
    Lawrance IC, Murray K, Hall A, Sung JJ, Leong R. A prospective comparative study of ASCA and ANCAp in Chinese and Caucasian IBD patients. Am J Gastroenterol. 2004;99:1286–1294.CrossRefGoogle Scholar
  23. 23.
    Buckland MS, Mylonaki M, Rampton D, Longhurst H. Serological markers (Anti Saccharomyces cerevisiae Mannan Antibodies and Antineutrophil Cytoplasmic Antibodies) in inflammatory bowel disease: Diagnostic utility and phenotypic correlation. Clin Diagn Lab Immunol. 2005;12:1328–1330.PubMedGoogle Scholar
  24. 24.
    Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA and Anti OmpC in children and young adults with Crohn’s disease and ulcerative colitis: Diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004;99:2235–2241.CrossRefPubMedGoogle Scholar
  25. 25.
    Vasiliauskas EA, Pleavy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn’s disease define a clinical subgroup. Gastroenterology. 1996;110:1810–1819.CrossRefPubMedGoogle Scholar
  26. 26.
    Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47:487–496.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Renato Mitsunori Nisihara
    • 1
    • 3
  • Wilson Beleski de Carvalho
    • 2
  • Shirley Ramos da Rosa Utiyama
    • 1
  • Heda Amarante
    • 2
  • Márcia Luiza Baptista
    • 2
  1. 1.Laboratory of ImmunopathologyFederal University of ParanáCuritibaBrazil
  2. 2.Department of GastroenterologyFederal University of ParanáCuritibaBrazil
  3. 3.Department of MedicineEvangelic UniversityCuritibaBrazil

Personalised recommendations